Summit, NJ – 10 de março de 2026 – Aveeno®*, the oat science skincare pioneer, today announced a three-year collaboration with Mayo Clinic. This collaboration will focus on research, education, and overall innovation and impact to elevate the industry and enhance the health and well-being of people worldwide.
As Aveeno® celebrates 80 years of trust in homes and hospitals, the brand reflects on a long-standing history of working with Mayo Clinic. The work includes the first mention of colloidal oatmeal in medical literature by Mayo Clinic physicians on the benefits of colloidal oatmeal baths for treating acute and chronic dermatoses [i]. Over subsequent decades, research has examined the role of colloidal oatmeal in dermatological treatment, including a pivotal clinical study demonstrating the superiority of Aveeno® Triple Oat® versus its vehicle control in relieving xerosis and pruritus[ii].
“We are constantly pushing for innovation, staying on the cutting edge of research and testing, especially within our skin health portfolio,” shared Dr. Caroline Tillett, Chief Scientific Officer at Kenvue, the maker of Aveeno®. “Aveeno® was the first brand to formulate colloidal oatmeal, and we are thrilled at the opportunity to collaborate with Mayo Clinic’s multi-disciplinary physicians to enhance our understanding of skin health. We care fiercely for those who use and recommend our products, and our goal is to deliver even greater solutions for ultimate skin health and wellness for both patients and consumers.”
The research programs are set to include preclinical and clinical investigations to advance scientific research on the power of Triple Oat® for compromised skin. Through research efforts that bring together dermatological research expertise and consumer skin health insights, Kenvue aims to advance skin wellness and education through its Aveeno® portfolio.
###
Sobre a Aveeno®
Aveeno® is the oat science skincare pioneer. A dermatologist-recommended brand for over 80 years & the leader of Oat Science with over 80 years of clinical research on Sensitive Skin. Clinically-proven for all ages, all skin-tones and all skin types – even sensitive & compromised skin.
Aveeno® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc.
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Aveeno®’s planned research and education activities and anticipated outcomes. Declarações prospectivas podem ser identificadas pelo uso de palavras como “planeja”, “espera”, “vai”, “prevê”, “estima” e outras palavras de significado semelhante. Aconselha-se que o leitor não confie nessas declarações prospectivas. Essas declarações são baseadas em expectativas atuais de eventos futuros. Se pressupostos subjacentes se provarem imprecisos, ou se riscos conhecidos ou desconhecidos ou incertezas se materializarem, os resultados reais poderão variar materialmente das expectativas e projeções da Kenvue Inc. e suas afiliadas.
Uma lista e descrições de riscos, incertezas e outros fatores podem ser encontradas nos registros da Kenvue com a Comissão de Valores Mobiliários, incluindo seu Relatório Anual no Formulário 10-K para o ano fiscal terminado em 28 de dezembro de 2025, e Relatórios Trimestrais subsequentes no Formulário 10-Q e outros registros, disponíveis no site a CVM (www.sec.gov) ou mediante solicitação da Kenvue. A Kenvue e seus afiliados renunciam a qualquer obrigação de atualizar qualquer declaração prospectiva como resultado de novas informações, eventos ou desenvolvimentos futuros ou outros.
[i][i] Kalaaaji, Amer N. & Wallo, Warren: A Randomized Controlled Clinical Study to Evaluate the Effectiveness of an Active Moisturizing Lotion With Colloidal Oatmeal Skin Protectant Versus Its Vehicle for the Relief of Xerosis - JDDonline - Journal of Drugs in Dermatology